Seres Therapeutics, Inc.
MCRB
$9.31
-$0.77-7.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -117.61% | 370.08% | 18.10% | 2.70% | 13.80% |
| Total Depreciation and Amortization | 632.55% | -1.13% | -8.92% | -85.20% | 525.42% |
| Total Amortization of Deferred Charges | -100.00% | -4.54% | 4.30% | 13.69% | 4.07% |
| Total Other Non-Cash Items | 97.06% | -1,585.43% | -35.22% | 767.00% | -119.37% |
| Change in Net Operating Assets | -214.04% | 42.34% | -81.77% | 40.52% | 32.47% |
| Cash from Operations | -12.12% | 12.89% | -12.98% | 25.82% | 19.84% |
| Capital Expenditure | 30.23% | -30.30% | -59.68% | 92.93% | 51.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -100.00% | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Investing | -100.06% | 10,740.48% | 2,200.00% | 92.93% | 51.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -89.80% | -- | -100.00% | 191.83% | 345.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 101.57% | -- | -100.00% | 191.83% | 345.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -744.74% | 88.55% | -132.88% | 60.58% | 29.63% |